The inhibition of PD-L1 disrupts its binding to PD-1, thereby preventing the suppression of T cell activation and proliferation, and enhancing the long-term immune response together with antitumor immunity against a wide range of cancers [71]. This evidence concerns the gene PDCD1 and cancer.